IL-17 antibody drugs, including Secukinumab (Cosentyx), Brodalumab (Siliq), and Ixekizumab (Taltz), have been approved for the treatment of autoimmune diseases such as psoriasis [101]. This evidence concerns the gene IL17A and autoimmune disease.